Generalised pruritus occurs in 25-50/ of cases of polycythaemia vera.
Normal ranges: *ferritin 15-300 .cg/l; tconjugated bile acids 0-6 ,umol/l.
Coniversion: SI to traditiontal iunits-Conjugated bile acids: 1 ,umol/l 0-5 mg/I.
Comment
Pizotifen is widely prescribed for migraine prophylaxis and possesses potent antihistamine and antiserotonin effects. It is well tolerated. Drowsiness and increased appetite often occur during treatment, but in most cases these usually prove mild and transient.5
Pruritus and its severity is a particularly subjective phenomenon; the trial was designed to reduce the placebo response, which in other antipruritic trials has been substantial. Pizotifen lessened the pruritus in six out of nine patients. Concentrations of conjugated bile acids were not related to the pruritus; the pruritic potential of iron deficiency in polycythaemia vera could not be separated from suboptimal disease control as judged by Coulter values.
Pruritus is often a severe and at times intractable symptom in polycythaemia vera; we found pizotifen to be an effective antipruritic agent. The mechanism of action is uncertain. In those patients who failed to respond it might have been valuable to increase the dose and prolong treatment, for in migraine prophylaxis a beneficial effect is seldom immediate and individual tailoring of dosage is often required. 
Case report
A 32-year-old woman was admitted in May 1980 for essential malignant hypertension with blood pressure of 220/130 mm Hg, retinal haemorrhages and cotton-wool exudates on fundoscopy, and creatinine clearance of 6 ml/min. Sodium nitroprusside, acebutolol, propranolol, clonidine, labetalol, dihydrallazine, and frusemide were tried in varying combinations and dosages, but the severe hypertension persisted.
She was readmitted on 15 July to try new antihypertensive combinations. After making sure that there was no underlying disease or, especially, lupus erythematosus (lupus erythematosus phenomenon and anti-DNA antibodies were absent) and that blood count was nearly normal (red cell count 2800 x 109/1, reticulocytes 84 x 109/1, white cell count 4-6 x 109/1, neutrophils 74 %, platelets 160x 109/1) we started a combination of captopril 100 mg/day, acebutolol 1200 mg/day, dihydrallazine 100 mg/day, and frusemide 40 mg/ day. She was discharged on 30 August, when her blood pressure was well controlled (140/60 mm Hg). Blood pressure subsequently increased to 200/120 mm Hg, and on 19 September we replaced acebutolol and dihydrallazine with labetalol 1200 mg then 800 mg a day. On 9 October blood pressure was 150/90 mm Hg, the fundus grade II, and creatinine clearance 12 ml/min.
She remained well until 24 January 1981, when she was readmitted because of hypotension and nose bleeding, which had started one week previously. Blood cell count showed packed cell volume 10 %, red blood cells 1000x 109/l, and white cell count 1 2x 109/l (neutrophils 34% and platelets 5 x 109/1). A bone-marrow aspirate showed reticular cells, bone cells, some lymphocytes, and many adipocytes but no erythropoietic and granulopoietic cell lines and no megaryocytes. Direct and indirect Coombs tests were negative. Because of the pancytopenia captopril was stopped on the first day of admission and labetalol 15 days later. Cell counts performed twice weekly over seven weeks showed no improvement, and she developed pneumonia. She was treated with antibiotics, packed red cells, and platelets. She did not improve so was admitted to a haematological intensive care unit. A bone-marrow graft was planned, but she died of septicemia on 20 March-that is, eight weeks after the pancytopenia was discovered.
Comment
This is the second reported case of fatal pancytopenia associated with treatment with captopril. Eighteen cases of leukopenia,5-4 among them three of agranulocytosis,' 2 4 have been reported during the past year. In four cases bone-marrow suppression was limited to the myeloid compartment,'-4 whereas in the present case, as in the one reported by Gavras et al,5 the erythroid and megakaryocytic cell lines were all suppressed. In four cases, as in ours, the patients had renal insufficiency. Since captopril is eliminated by the kidney, toxic concentrations of the drug may have developed. Other drugs were given in three cases, including immunosuppressives in one, and one patient was suspected of having underlying blood dyscrasia,4 but our patient had no underlying disease and the combined antihypertensive drugs are not known to cause haematological toxicity. This report emphasises that caution should be used in all patients with renal failure and that frequent blood counts should be made in such patients during treatment with captopril. Effect of sulphonylurea on insulin secretion and glucose control in insulin-treated diabetics Endogenous insulin secretion in insulin-dependent diabetics has an important role in assisting blood glucose control.' 2 Stimulation of endogenous insulin secretion by treatment with a sulphonylurea might therefore be advantageous. We carried out a cross-over trial of glibenclamide and placebo in patients with diabetes of recent onset, who might be expected to have some endogenous insulin secretion, to determine whether the sulphonylurea increased the insulin secretion or improved diabetic control.
Patients, methods, and results
Eight diabetic men volunteered for the study. One was withdrawn because of a hypoglycaemic reaction to the active treatment, but his previous 24-hour plasma glucose profile, during placebo treatment, had shown a glucose concentration of 1-2 mmol/l (180-360 mg/100 ml) on several occasions. The seven other patients received a constant insulin dose throughout the study and were analysed together. All were aged 20-47 and had had diabetes for a mean of 3 5 years (range 0-5-8 years).
Six patients were treated with Ultratard insulin as a basal supplement, four with additional twice-daily Actrapid insulin to cover meals and two with Actrapid and Semitard in the morning and Actrapid and Ultratard in the evening.' One patient was treated with Actrapid and Retard twice daily. The mean dose was 0 7 U/kg (range 0-31-1-0 U/kg). The patients were treated double blind with glibenclamide 10 mg twice daily or placebo tablets for four weeks and then admitted at 1730 for a 24-hour profile, blood samples being taken via a forearm intravenous Teflon cannula. They were given normal food and insulin treatment, were up and dressed, but took less exercise than usual. Blood glucose was measured by the glucose oxidase method (Boehringer GOD-perid).
C-peptide, secreted in equimolar amounts with insulin, provides a means of monitoring endogenous insulin secretion in insulin-treated patients. Plasma C-peptide concentration was measured by immunoassay using antiserum and "25I-labelled C-peptide and charcoal phase separation (precision ±0 02 (±1 SD) nmol/l). The antibody-bound proinsulin was separated by polyethylene glycol precipitation.4 The mean normal fasting plasma C-peptide concentration was 0-35 nmol/l (105 mg/100 ml) (range 0-1-0-5 nmol/l (0-3-1-5 mg/100 ml)), rising to a mean peak of 1-2 nmol/l (3-6 mg/100 ml) one hour after meals. Haemoglobin Al, was assessed by isoelectric focusing, the normal range being 5 8-8 0 % total haemoglobin. Statistical tests included the paired t test.
Four patients had immunoreactive C-peptide while taking the placebo; none of the three others developed immunoassayable C-peptide when taking glibenclamide. The plasma C-peptide concentration in these four patients did not increase substantially with treatment (mean (± SD) 24-hour concentration 0 14 ±0 08 nmol/l with placebo v 0 21 ±0 12 nmol/l with treatment (0-4±02 v 06 ±03 mg/100 ml)). Blood glucose control, as measured by 24-hour profiles (figure), did not improve in either the four patients with C-peptide (mean 24-hour fasting plasma glucose concentration 7-7 v 7-4 mmol/l (138-7 v 133 3 mg/100 ml)) or the three patients without C-peptide (mean 10 9 v 12 5 mmol/l (32-7 v 37-5 mg/100 ml)). Haemoglobin Alc showed little difference (mean 10 8 v 9 5 %O) except in one patient (9-6 v 5-9 %/O), who received the least insulin (20 U Ultratard/day alone) and had the highest mean 24-hour plasma C-peptide concentration, which increased from 0-25 to 0 39 nmol/l (0 7 to 1 1 mg/100 ml) with glibenclamide treatment. 
Comment
This study suggests that most insulin-treated patients would receive little benefit from stimulation of endogenous insulin secretion with a sulphonylurea. Patients with diabetes of recent onset with considerable beta-cell secretion might benefit but already have fairly good diabetes control.' Patients with little or no endogenous insulin secretion and poor diabetes control do not appear to be improved by treatment with a sulphonylurea. Any affect of sulphonylurea on insulin receptors5 is unlikely to help control in insulin-dependent diabetics, in whom poor control is due mainly to lack of physiological meal-related insulin responses rather than the degree of overall insulin sensitivity. 
